Physician profile
Gregor Paronian
NPI 1366627945
$18,832.77
in general payments reported to CMS, 2019-2025
65 companies · $3,266 in 2025
The $3,266 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,612 · 2020: $1,287 · 2021: $3,149 · 2022: $2,841 · 2023: $3,474 · 2024: $3,204 · 2025: $3,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,944.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,850.27 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,196.11 | 2019-2025 | Farxiga, Breztri |
| Amgen INC. | $1,741.45 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $881.70 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $776.90 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $754.52 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $705.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $667.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $589.79 | 2021-2025 | Rexulti |
| Pfizer INC. | $575.42 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $509.80 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Amarin Pharma, INC. | $464.05 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.22 | 2020-2025 | Jardiance |
| Almatica Pharma LLC | $403.79 | 2022-2025 | Loreev Xr, Gralise |
| Kowa Pharmaceuticals America, INC. | $396.31 | 2019-2025 | Zoryve, Livalo, Seglentis |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregor Paronian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.